Valneva and VBI Vaccines Ink Partnership Deal Over Hepatitis B Vaccine
Valneva and VBI Vaccines have entered a partnership deal over VBI Vaccines’ hepatitis B vaccine PreHevbri.
PreHevbri is the only three-antigen vaccine approved in Europe for hepatitis B. It’s also FDA-approved for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years and older.
Under the terms of the agreement, Valneva will promote and distribute PreHevbri throughout certain European countries, which initially include the UK, Sweden, Norway, Denmark, Finland, Belgium and the Netherlands. The vaccine is expected to be available in those countries in early 2023.
The financial terms of the partnership deal were not disclosed.